Results 31 to 40 of about 20,748 (167)
Background The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under ...
Brady L. Stein +9 more
doaj +1 more source
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Objectives Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the ...
Timothy Devos +4 more
doaj +1 more source
Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson +4 more
wiley +1 more source
Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis
There is prevailing evidence to suggest a decisive role for platelet-derived growth factors (PDGF) and their receptors in primary myelofibrosis. While PDGF receptor β (PDGFRβ) expression is increased in bone marrow stromal cells of patients correlating ...
Frederike Kramer +5 more
doaj +1 more source
Objective Myelofibrosis is a rare chronic myelolymphoproliferative disease and is associated with increased risk of venous thromboembolism. The objective of this study is to retrospectively evaluate patients with primary myelofibrosis who underwent ...
Marco Di Girolamo +5 more
doaj +1 more source
ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki +6 more
wiley +1 more source
ABSTRACT Purpose To improve accuracy of apparent diffusion coefficient (ADC) measurement across different bone‐marrow (BM) sites for myelofibrosis (MF) patients. Methods Vendor‐provided ADC gradient nonlinearity correction (GNC) was implemented for 41 MF study subjects on a 3T clinical scanner.
Dariya Malyarenko +9 more
wiley +1 more source
Diffuse osteolytic lesions in leukemic transformation of myelofibrosis [PDF]
Myelofibrosis is a clonal myeloproliferative disorder characterized by splenomegaly, abnormal deposition of reticulin and collagen in the bone marrow, extramedullary hematopoiesis, dacryocytosis and leukoerythroblastic blood smear.
Jurišić Vladimir +3 more
doaj +1 more source
Summary Genomic technologies including next‐generation sequencing (NGS) and arrays for cytogenetic anomalies are now standard of care in England for the diagnostic evaluation of patients with suspected haematological malignancies. Challenges remain in the management of potential germline findings as a result of NGS panels and copy number variant ...
B. Speight +12 more
wiley +1 more source
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson +5 more
wiley +1 more source

